Charter Life Sciences

Prevacept Infection Control is a clinical-stage company focused on developing and commercializing products that prevent infections associated with indwelling catheters.

Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia from inside the GI lumen. Xlumena was founded in 2007 and is based in Mountain View, California.

Amaranth Medical, Inc. is a medical device company based in Mountain View, California, with research and manufacturing operations in Singapore and Silicon Valley. Founded in 2005, the company specializes in developing and manufacturing bioresorbable scaffolds for vascular and nonvascular applications. Its flagship product, FORTITUDE, is a bioresorbable coronary scaffold designed to assist arteries during the remodeling process after interventional procedures. These scaffolds utilize advanced polymer structure and processing technology, allowing them to gradually lose mechanical strength while maintaining vessel function and flexibility. Amaranth Medical aims to redefine interventional cardiology by providing versatile scaffolds that offer long-term clinical benefits without leaving behind permanent metal implants, thereby striving to establish a new global standard of care in stent interventions.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia from inside the GI lumen. Xlumena was founded in 2007 and is based in Mountain View, California.

Prevacept Infection Control is a clinical-stage company focused on developing and commercializing products that prevent infections associated with indwelling catheters.

CoRepair is a company that develops a radio-frequency device system for the treatment of congestive heart failure.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels.

Visioneering Technologies, Inc., based in Alpharetta, Georgia, is a medical device company focused on advancing vision care through innovative products. The company specializes in the design, manufacture, and distribution of NaturalVue daily disposable multifocal contact lenses, which cater to adults with presbyopia and children with myopia. These lenses are designed to provide clear vision at near, intermediate, and distance ranges, significantly improving patient outcomes and easing the fitting process for eye care professionals. Founded by Dr. Richard A. Griffin, who possesses extensive experience in optometry and optical engineering, Visioneering holds fourteen patents worldwide aimed at addressing the challenges of presbyopia and myopia. The company combines expertise from various sectors, including clinical, marketing, engineering, manufacturing, and regulatory, leveraging the knowledge of seasoned professionals to create effective solutions for vision care.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

CoRepair is a company that develops a radio-frequency device system for the treatment of congestive heart failure.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Mirabilis Medic is a medical device company that focuses on the treatment of uterine fibroids that is a common problem for women. Its products include a non-invasive therapeutic solution for use by gynecologists that allows them to treat pathological tissue deep inside the body without incisions, punctures, or other damage to intervening tissue. The company was founded in 2004 and is based in Bothell, Washington.

KFx Medical specializes in developing and manufacturing innovative soft tissue fixation implants tailored for orthopedic sports medicine. The company offers a range of products designed for tissue fixation, which can be directly placed into bones with or without sutures. These implants are applicable in various orthopedic surgical procedures, allowing surgeons to effectively reattach tissue in regions such as the shoulder, knee, foot, and ankle. KFx Medical collaborates closely with leading orthopedic surgeons to create advanced technologies and reliable surgical implants, ultimately aiming to improve surgical outcomes for patients.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company specializes in developing nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., CoMentis underwent a name change in 2007 following its merger with Zapaq, Inc., which enhanced its focus on neurovascular diseases. Based in South San Francisco, California, CoMentis is committed to advancing therapeutic options for conditions that significantly impact cognitive function.

Amaranth Medical, Inc. is a medical device company based in Mountain View, California, with research and manufacturing operations in Singapore and Silicon Valley. Founded in 2005, the company specializes in developing and manufacturing bioresorbable scaffolds for vascular and nonvascular applications. Its flagship product, FORTITUDE, is a bioresorbable coronary scaffold designed to assist arteries during the remodeling process after interventional procedures. These scaffolds utilize advanced polymer structure and processing technology, allowing them to gradually lose mechanical strength while maintaining vessel function and flexibility. Amaranth Medical aims to redefine interventional cardiology by providing versatile scaffolds that offer long-term clinical benefits without leaving behind permanent metal implants, thereby striving to establish a new global standard of care in stent interventions.

Bullhorn, Inc. specializes in developing cloud-based staffing and recruiting software tailored for startups, small to medium-sized businesses, and enterprises. Founded in 1999 and headquartered in Boston, Massachusetts, the company provides a range of products, including applicant tracking systems, business intelligence tools, CRM solutions, onboarding software, and VMS integration. These offerings streamline the recruitment lifecycle by automating processes such as candidate management, time and expense tracking, and billing. Bullhorn serves various sectors, including professional staffing, healthcare, executive search, commercial, and nonprofit industries. With additional offices across Europe, Asia, and North America, Bullhorn aims to empower companies with data capture and customer insight technology, enhancing their ability to attract and retain clients.

Kereos, Inc., a biotechnology company, develops targeted molecular imaging agents and therapeutics to detect and treat cancer and cardiovascular disease. The company offers KI-0001, a magnetic resonance imaging (MRI) agent for tumor detection that finds tumors and highlights growing regions in the tumor margin; and KI-100X, a targeted chemotherapeutics for solid tumors, which reduces angiogenesis in tumor and atherosclerosis models, as well as inhibits tumor growth. It also provides KI-0002, an MRI agent for cardiovascular disease detection via an undisclosed biomarker; KI-1004, an anti-restenotic that inhibits restenosis while preserving re-endotheliazation in angioplasty models; and KM-4419, a targeted chemotherapeutic for solid tumors that synergizes with several chemotherapeutics in blocking tumor growth and increasing survival. In addition, the company works with pharmaceutical and imaging companies for the development and commercialization of cardiovascular disease MRI agents, as well as development of molecular imaging systems. Kereos, Inc. was founded in 1999 and is based in St. Louis, Missouri.

KFx Medical specializes in developing and manufacturing innovative soft tissue fixation implants tailored for orthopedic sports medicine. The company offers a range of products designed for tissue fixation, which can be directly placed into bones with or without sutures. These implants are applicable in various orthopedic surgical procedures, allowing surgeons to effectively reattach tissue in regions such as the shoulder, knee, foot, and ankle. KFx Medical collaborates closely with leading orthopedic surgeons to create advanced technologies and reliable surgical implants, ultimately aiming to improve surgical outcomes for patients.